Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis.

ABSTRACT:

Background

Immune checkpoint inhibitors may be associated with multiple immune-related toxicities. Cardiovascular adverse effects are underreported in clinical trials.

Methods

We conducted a systematic review and meta-analysis to evaluate cardiovascular adverse effects incidence among patients with solid tumors receiving immune checkpoint inhibitors in randomized clinical trials and the relative risk of presenting these effects compared to placebo or best supportive care. The search was conducted through MEDLINE, Embase, and Scopus databases from January 1st, 2010 until July 1st, 2020. Outcomes were reported following Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.

Results

57 randomized clinical trials including 12,118 patients

SUBMITTER: Xavier CB 

PROVIDER: S-EPMC8898968 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature